ALTERITY THERAPEUTICS LIMITED ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
On January 24, 2023, Alterity Therapeutics Limited (the "Company") received formal notification from The Nasdaq Stock Market LLC confirming that the Company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"), which requires that the Company's American Depositary Shares ("ADS") maintain a minimum bid price of at least $1.00 per ADS, and that the matter is now closed.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Alterity Therapeutics Ltd. published this content on 25 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 January 2023 11:07:06 UTC.
